Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) reached 17.04% versus a 1-year low price of $1.35. The stock was last seen 11.27% higher, reaching at $1.58 on Nov. 3, 2017. At recent session, the prices were hovering between $1.3614 and $1.6. This company shares are 216.46% off its target price of $5 and the current market capitalization stands at $33.12M. The recent change has given its price a -6.63% deficit over SMA 50 and -66.31% deficit over its 52-week high. The stock witnessed -11.73% declines, -21% declines and -61.65% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found IMMY’s volatility during a week at 8.22% and during a month it has been found around 12.26%.Imprimis Pharmaceuticals, Inc. (IMMY) Top Holders
Institutional investors currently hold around $6 million or 24.2% in IMMY stock. Look at its top three institutional owners. Opaleye Management Inc. owns $1.41 million in Imprimis Pharmaceuticals, Inc., which represents roughly 4.27% of the company’s market cap and approximately 23.57% of the institutional ownership. Similar statistics are true for the second largest owner, Marathon Asset Management Lp, which owns 792,434 shares of the stock are valued at $1.25 million. The third largest holder is Institutional & Family Asset Management, Llc, which currently holds $1.1 million worth of this stock and that ownership represents nearly 3.31% of its market capitalization.
At the end of 06/30/2017 reporting period, 13 institutional holders increased their position in Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) by some 337,570 shares, 9 decreased positions by 184,229 and 6 held positions by 3,061,086. That puts total institutional holdings at 3,582,885 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 3,824 shares while 6 institutional investors sold out their entire positions totaling 133,019 shares.Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) Insider Trades
Multiple company employees have indulged in significant insider trading. Imprimis Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Kammer Robert J has sold 10,000 shares of Imprimis Pharmaceuticals, Inc. (IMMY) in trading session dated Jul. 17, 2017. These shares are worth $30,500 and were traded at $3.05 each. The SEC filing shows that Lindstrom Richard L Md performed a purchase of 100,000 shares. The Director added these shares by way of transaction on Dec. 19, 2016. The company’s shares were assimilated at $1.79 per share worth to an investment of some $179,000 on account of Lindstrom Richard L Md.
CFO, Boll Andrew R., purchased 39,000 common shares of Imprimis Pharmaceuticals, Inc. (IMMY) in the open market. In a transaction dated Dec. 19, 2016, the shares were bought at an average price of $1.79, giving away a sum of $69,810. After this purchase, 54,000 common shares of IMMY are directly owned by the insider, with total stake valued at $85,320.
In the transaction dated Dec. 19, 2016, the great number of shares acquired came courtesy the CEO; Baum Mark L added a total of 156,000 shares at an average price of $1.79, amounting to approximately $279,240. The insider now directly owns 442,126 shares worth $698,559.